Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 18/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867826 | 0.88 | MKNK1 (0.45) | MKNK1MKNK2 | |
| SCHEMBL3865528 | 0.87 | MKNK1 (0.45) | MKNK1MKNK2IRAK4 | |
| SCHEMBL3865962 | 0.85 | MKNK1 (0.47) | MKNK1DYRK3DYRK1ADYRK2 | |
| SCHEMBL3866437 | 0.85 | MKNK1 (0.43) | MKNK1MKNK2DYRK3DYRK1ADYRK2 | |
| SCHEMBL3865738 | 0.84 | MKNK1 (0.42) | MKNK1IRAK4 | |
| SCHEMBL3868140 | 0.84 | MKNK1 (0.41) | MKNK1MKNK2DYRK3DYRK1ADYRK2 | |
| SCHEMBL3866029 | 0.83 | MKNK1 (0.42) | MKNK1DYRK3DYRK1ADYRK2 | |
| SCHEMBL3866313 | 0.83 | DYRK3 (0.45) | MKNK1DYRK3DYRK1ADYRK2 | |
| SCHEMBL3870153 | 0.82 | MKNK1 (0.42) | MKNK1DYRK3DYRK1ADYRK2 | |
| SCHEMBL3870154 | 0.82 | MKNK1 (0.47) | MKNK1DYRK3DYRK1ADYRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044071-A1 | OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-08 | — | — | EP | claimed |
| WO-2007147646-A1 | OXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | claimed |
| US-8653076-B2 | Oxo-substituted imidazo[1,2B]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093475-A1 | Oxo-substituted imidazo[1,2b]pyridazines, their preparation and use as pharmaceuticals | CDK2, CDK1, MAP4K2 | MKNK1 299/4885MKNK2 203/4885DYRK3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.